Purine nucleoside — mediated immobility in mice: Reversal by antidepressants
Tóm tắt
In the forced swimming-induced immobility (despair) test model, adenosine, and 2-chloroadenosine treatment prolonged the immobilization period in mice. Dipyridamole, which is known to inhibit adenosine uptake, potentiated the adenosine effect. The purinoceptor antagonists caffeine and theophylline blocked purine nucleoside-induced enhancement of immobilization. Tricyclic antidepressants such as imipramine and desipramine, the MAO inhibitor tranylcypromine, and amphetamine, a psychostimulant, reversed purine nucleoside-induced immobility. On the other hand, quipazine, fluoxetine, and amitriptyline failed to reverse purine nucleosides-induced prolongation of immobility. None of the antidepressants in the doses investigated had any effect by themselves. Reserpine also prolonged forced swimming-induced immobility in mice. The antidepressants fluoxetine and quipazine, but not methylxanthine pretreatment, reversed reserpine-induced immobility in this test model. These results indicate that adenosine and 2-chloroadenosine probably reduce norepinephrine outflow through their action on presynaptic purinoceptors on noradrenergic neurons and thereby cause prolongation of immobility in animals.
Tài liệu tham khảo
Alfonso S, O'Brien GS (1971) Mechanism of enhancement of adenosine action by dipyridamole and lidoflazine in dogs. Arch Int Pharmacodyn Ther 194:181–186
Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
Clanachan AS, Johns A, Paton DM (1977) Presynaptic inhibitory actions of adenine nucleotides and adenosine on neurotransmission in the rat vas deferens. Neuroscience 2:597–602
Daly JW, Bruns RF, Snyder SH (1981) Adenosine receptors in the central nervous system: Relationship to the central actions of methylxanthines. Life Sci 28:2083–2097
Dunwiddie TV, Worth T (1982) Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther 220:70–76
Fuller RW, Wong DT (1977) Inhibition of serotonin reuptake. Fed Proc 36:2154–2158
Haulica I, Ababei L, Branisteanu D, Topoliceanu F (1973) Preliminary data on the possible hypnogenic role of adenosine. J Neurochem 21:1019–1020
Holmgren M, Hednar T, Nordberg G, Mellstrand T (1983) Antinociceptive effects in the rat of an adenosine analogue, N6-phenylisopropyladenosine. J Pharm Pharmacol 35:679–680
Hong E, Sancilio LF, Vargas R, Pardo EG (1969) Similarities between the pharmacological actions of quipazine and serotonin. Eur J Pharmacol 6:274–280
Hopkins SV (1973) The potentiation of the action of adenosine on the guinea-pig heart. Biochem Pharmacol 22:341–348
Kalsner S (1975) Adenosine and dipyridamole actions and interactions on isolated coronary artery strips of cattle. Br J Pharmacol 55:439–445
Klabunde RE (1983) Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 93:21–26
Kulkarni SK, Mehta AK (1983) Purinoceptors: A new concept. Indian J Pharm Sci 45:150–157
Kulkarni SK, Mehta AK (1984a) P1-purinoceptor antagonism by clonidine in the rat caecum. Life Sci 34:2273–2277
Kulkarni SK, Mehta AK (1984b) The pharmacology of purine nucleosides and nucleotides. Drugs of Today 20:217–232
Mehta AK, Kulkarni SK (1983) Effect of purinergic substances on rectal temperature in mice: Involvement of P1-purinoceptors. Arch Int Pharmacodyn Ther 264:180–186
Mehta AK, Kulkarni SK (1984) Mechanism of potentiation by diazepam of adenosine response. Life Sci 34:81–86
Mustafa SJ (1979) Effect of coronary vasodilator drugs on the uptake and release of adenosine in cardiac cells. Biochem Pharmacol 28:2617–2624
Mustafa SJ (1980) Cellular and molecular mechanism(s) of coronary flow regulation by adenosine. Mol Cell Biochem 31:67–87
Nagatani T, Sugihara T, Kodaira R (1984) The effect of diazepam and of agents which change GABAergic functions in immobility in mice. Eur J Pharmacol 97:271–275
Natan LB, Chaillet P, Lecomte JM, Marçais H, Uchida G, Costentin J (1984) Involvement of endogenous enkephalins in the mouse behavioral despair' test. Eur J Pharmacol 97:301–304
Paton DM (1981) Presynaptic neuromodulation mediated by purinergic receptors. In: Burnstock G (ed) Purinergic receptors. Chapman & Hall, London, pp 199–219
Porsolt RD, Anton G, Blavat N, Jalfre M (1978a) Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379–391
Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M (1979) Immobility induced by forced swimming in rats: Effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 57:201–210
Porsolt RD, Bertin A, Jalfre M (1977a) Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336
Porsolt RD, Bertin A, Jalfre M (1978b) Behavioural despair in rats and mice: Strain differences and the effects of imipramine. Eur J Pharmacol 51:291–294
Porsolt RD, Le Pichon M, Jalfre M (1977b) Depression: A new animal model sensitive to antidepressant treatments. Nature 226:730–732
Schechter MD, Chance WT (1979) Non-specificity of “Behavioural despair” as an animal model of depression. Eur J Pharmacol 60:139–142
Stone TW (1981) Physiological roles for adenosine and adenosine-5′-triphosphate in the nervous system. Neuroscience 6:523–555
Su C (1977) Adrenergic and noradrenergic vasodilator innervation. In: Carrier O Jr, Shibata S (eds) Factors influencing vascular reactivity. Igaku Shoin, Tokyo, pp 156–168
Su C (1981) Purinergic receptors in blood vessels. In: Burnstock G (ed) Purinergic receptors. Chapman & Hall, London, pp 95–117
Su C (1983) Purinergic neurotransmission and neuromodulation. Ann Rev Pharmacol Toxicol 23:397–411